SELEXIS AND KBI BIOPHARMA ENTER INTO AGREEMENTS WITH IMMATICS FOR INTEGRATED APPROACH TO ADVANCE IMMATICS TCR BISPECIFIC PROGRAM TOWARDS IND
Read More
KBI BIOPHARMA ENTERS COMMERCIAL MANUFACTURING AGREEMENT WITH AM-PHARMA TO PREPARE FOR THE COMMERCIAL LAUNCH OF LEAD PROGRAM IN ACUTE KIDNEY DISEASE
DURHAM TECH AND KBI BIOPHARMA PARTNER TO BOOST DIVERSITY AND CREATE LIFE SCIENCES JOB OPPORTUNITIES FOR NORTH CAROLINA STUDENTS AND VETERANS
MAXIMUM OUTPUT STARTS WITH OPTIMIZED UPSTREAM PROCESSING
KBI BIOPHARMA EXPANDS US OPERATIONS WITH NEW $150 MILLION COMMERCIAL MANUFACTURING FACILITY BASED IN RTP, NORTH CAROLINA
JSR LIFE SCIENCES EXPANDS ITS EUROPEAN GENE-TO-GMP BIOLOGICS MANUFACTURING FACILITIES FOR SELEXIS AND KBI BIOPHARMA IN GENEVA, SWITZERLAND
ABSCI CLOSES $15.4 M IN SERIES D FUNDING TO ACCELERATE GROWTH AND SCALE DISRUPTIVE PROTEIN PRINTINGTM TECHNOLOGY, ANNOUNCES EXCLUSIVE CO-MARKETING...
ZyVersa Therapeutics to Advance Development of it's Lead Inflammasome Inhibitor with Selexis and KBI Biopharma's Integrated Development Platform
KBI Biopharma Inc. and Selexis SA Form Joint Scientific Advisory Board Industry Experts to Provide Strategic Guidance as the Companies Advance...
CytoSen Therapeutics and KBI Biopharma Enter into Strategic Partnership to Manufacture NK Cells and Nanoparticles Implementing scalable manufacturing...
